Localized Leiomyosarcoma Biomarker Protocol

Overview

About this study

The purpose of this study is to evaluate the association between tumor characteristics assessed by contrast-enhanced MRI and location with presence of circulating tumor DNA (ctDNA) in patients with localized, high-grade leiomyosarcoma [Time Frame: 2 years ].

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Patients with localized leiomyosarcoma (LMS) of extremity, body wall or
retroperitoneum.

- Grade 2 or 3, or high-grade LMS.

- Tumor size >5 cm in greatest dimension.

- Primary tumor amenable to complete resection.

- There is no age requirement.

- Participant agrees to receive neoadjuvant doxorubicin and ifosfamide combination
chemotherapy.

- If pre-operative radiation is administered, it must be administered after
chemotherapy. Post-operative radiation may be administered.

- Archival tumor tissue (either frozen sample, tissue block containing tumor, or minimum
of 4 unstained slides and 1 H&E stained slide) from diagnostic or pre-treatment biopsy
available for study research.

Exclusion Criteria:

  • Any exception to Inclusion Criteria.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/5/23. Questions regarding updates should be directed to the study team contact.

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Brittany Siontis, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available